A lung-activated inhaled corticosteroid with novel distribution and discharge properties.

This acceptance of Alvesco in the united kingdom is another main milestone for ALTANA Pharma. Other approvals will observe, so that individuals in many countries can reap the benefits of Alvesco.. ALTANA gets MHRA approval for Alvesco ALTANA AG has announced that the Medicines and Healthcare Items Regulatory Company in britain has granted ALTANA Pharma advertising acceptance for Alvesco , a lung-activated inhaled corticosteroid with novel distribution and discharge properties. Alvesco is indicated as prophylactic treatment of persistent asthma in adults. The United Kingdom can be serving as the Reference Member Condition for the European Mutual Acknowledgement Procedure which will be initiated to gain marketing authorization for Alvesco in participating countries.‘The initial fifty % of 2010 was centered on executing our broad development strategy designed to leverage the potential of pimavanserin over a variety of neurological and psychiatric indications with huge unmet medical needs together with our collaborative partner, Biovail,’ said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA Pharmaceuticals. ‘We recently initiated a new Stage III trial in Parkinson’s disease psychosis and we are continuing to arrange for a Stage II feasibility study in Alzheimer’s disease psychosis and a Phase III co-therapy trial in schizophrenia. We believe that pimavanserin along with ACADIA’s other product applicants placement us with multiple attractive product and commercial opportunities providing significant growth potential.’ Related StoriesReduced conflict-related brain activity associated with higher risk for psychosisArticle explores viewpoints on part of mild cognitive impairment in Parkinson's diseaseGene therapy prevents neuronal loss of life, disease effects in experimental model of PDRevenues increased to $2.3 million for the second quarter of 2010 from $1.8 million for the next quarter of 2009.